![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Labeling Supplement for Celebrex
FDA Approves Labeling Supplement for Celebrex
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
July 2, 2018
The FDA approved a labeling supplement for Pfizer’s anti-inflammatory drug Celebrex (celecoxib).
The supplement will include results from a postmarketing study that found at its lowest dose the drug had a similar cardiovascular safety profile to naproxen and ibuprofen.
The study found that at 100 mg twice daily, the lowest approved dose for the drug, it is non-inferior to ibuprofen in the range of 600-800 mg three times daily or naproxen at 375-500 mg twice daily.
Upcoming Events
-
21Oct